Amphastar Pharmaceuticals (AMPH) Interest & Investment Income (2013 - 2026)

Amphastar Pharmaceuticals has reported Interest & Investment Income for 14 years, with the latest figure at $2.3 million in Q2 2026.

• On a quarterly basis, Interest & Investment Income rose 19.05% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $9.4 million, a 7.18% increase from a year earlier, with the FY2025 full-year figure at $8.7 million, down 18.22% from the prior year.
• Interest & Investment Income was $2.3 million for Q2 2026 at Amphastar Pharmaceuticals, down from $2.4 million in the prior quarter.
• The five-year high for Interest & Investment Income was $3.3 million in Q2 2024, with the low at $181000.0 in Q1 2022.
• Average Interest & Investment Income over 5 years is $1.7 million, with a median of $2.2 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income surged 410.5% in 2023, then tumbled 42.43% in 2025.
• Over 5 years, Interest & Investment Income stood at $580000.0 in 2022, then jumped by 297.07% to $2.3 million in 2023, then decreased by 0.48% to $2.3 million in 2024, then climbed by 5.72% to $2.4 million in 2025, then dropped by 5.61% to $2.3 million in 2026.
• The last three Interest & Investment Income figures came in at $2.3 million (Q2 2026), $2.4 million (Q1 2026), and $2.4 million (Q4 2025), per Business Quant data.